Arsenic trioxide: Acute promyelocytic leukemia and beyond

被引:45
作者
Bachleitner-Hofmann, T [1 ]
Kees, M [1 ]
Gisslinger, H [1 ]
机构
[1] Univ Vienna, Dept Internal Med 1, Div Haematol & Blood Coagulat, A-1090 Vienna, Austria
关键词
arsenic trioxide; acute promyelocytic leukemia; apoptosis; reactive oxygen species; glutathione redox system;
D O I
10.1080/1042819021000002857
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Arsenic containing treatments have a history of over two millenniums. Recently, arsenic trioxide (As2O3) has been introduced into the treatment of both de novo and relapsed acute promyelocytic leukemia (APL), with remarkable clinical success. Several investigations using both freshly isolated APL blast cells as well as APL-derived tumor cell lines have shown that the main mechanism by which As2O3 exerts its antileukemic activity in APL is induction of apoptosis in the leukemic cell population. Recently, it has become evident that the apoptotic effects of As2O3 are not restricted to APL cells but may also be observed in malignant cells of non-APL origin. In the present review, history, current clinical use as well as future perspectives of As2O3 therapy in both hematologic and solid malignancies are discussed, with special emphasis being put on the potential future role of As2O3 in the treatment of non-APL tumors. Of particular importance, enhancing agents suited to increase As2O3-sensitivity in less sensitive tumors (e.g. ascorbic acid) are also addressed.
引用
收藏
页码:1535 / 1540
页数:6
相关论文
共 36 条
[1]   Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein [J].
Akao, Y ;
Mizoguchi, H ;
Kojima, S ;
Naoe, T ;
Ohishi, N ;
Yagi, K .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (04) :1055-1060
[2]  
[Anonymous], 1878, AM J MED SCI
[3]   Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia? [J].
Bachleitner-Hofmann, T ;
Gisslinger, B ;
Grumbeck, E ;
Gisslinger, H .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (03) :783-786
[4]  
Chen GQ, 1997, BLOOD, V89, P3345
[5]  
Chen GQ, 1996, BLOOD, V88, P1052
[6]  
CORREIA MA, 1989, BASIC CLIN PHARM, P747
[7]   Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system [J].
Dai, J ;
Weinberg, RS ;
Waxman, S ;
Jing, YK .
BLOOD, 1999, 93 (01) :268-277
[8]  
FINCH RG, 1982, MODERN PHARM, P698
[9]   Arsenic as a therapeutic agent in chronic myelogenous leukemia - Preliminary report [J].
Forkner, CE ;
Scott, TTM .
JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1931, 97 :0003-0005
[10]   Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells [J].
Grad, JM ;
Bahlis, NJ ;
Reis, I ;
Oshiro, MM ;
Dalton, WS ;
Boise, LH .
BLOOD, 2001, 98 (03) :805-813